Vnitr Lek 2022, 68(1):58-63 | DOI: 10.36290/vnl.2022.008
Differential diagnosis of pituitary enlargement
- 1 Ústřední vojenská nemocnice, Interní klinika 1. LF UK a ÚVN, Praha
- 2 Ústřední vojenská nemocnice, Radiodiagnostické oddělení, Praha
- 3 Ústřední vojenská nemocnice, Neurochirurgická a neuroonkologická klinika 1. LF UK a ÚVN, Praha
Enlargement of the pituitary gland is heterogenous in the etiology. Common causes of pituitary enlargement are physiological hypertrophy during pregnancy, primary and secondary tumors, autoimmune hypophysitis including side effects of anticancer therapy with check-point inhibitors. Terms like hypertrophy, hyperplasia, sellar expansion and hypophysitis are commonly used to describe enlargement of the pituitary gland on MR scan regardless its etiology. The most common pathology causing pituitary gland enlargement is pituitary adenoma. Magnetic resonance imaging can differentiate pituitary tumors from diffuse enlargement due to hypophysitis in most but not all cases. Changes on imaging during time or response to pharmacotherapy might help determine the final diagnosis in uncertain cases. We present a case report of a young woman with sellar expansion due to prolonged untreated peripheral hypothyroidism mimicking pituitary adenoma. Interdisciplinary cooperation of endocrinologist, radiologist and neurosurgeon is crucial in determining the diagnosis.
Keywords: hypophysitis, hypothyroidism, immune checkpoint inhibitors, pituitary tumor, sellar expansion.
Published: February 14, 2022 Show citation
References
- Osborn AG, Salzman KL, Jhaveri MD et al. Diagnostic imaging Brain, 3rd ed. Elsevier: 2010: 1060-62. ISBN 978-0-323-37754-6.
- Bonneville JF, Cattin F, Nagi S et al. MRI of the Pituitary Gland. Springer: 2016: 53-55. ISBN 978-3-319-29043-0.
Go to original source...
- Hána V. Hypopituitarismus a diabetes insipidus centralis: průvodce ošetřujícího lékaře. In: Hugo J.Farmakoterapie pro praxi. Maxdorf: Praha:2011:10-21. ISBN 978-80-7345-241-4.
- Horvath E, Kovacs K, Scheithauer BW. Pituitary hyperplasia. Pituitary 1999;1:169-79.
Go to original source...
Go to PubMed...
- Marek J. Hypofýza a její onemocnění. Sanquis 2005;40:24.
Go to original source...
- Netuka D, Masopust V, Beneš V. Léčba adenomů hypofýzy. Cesk Slov Neurol N 2011;74:240-253.
- Howlett TA, Levy MJ, Robertson IJ. How reliably can autoimmune hypophysitis be diagnosed without pituitary biopsy. Clin Endocrinol (Oxf) 2010;73:18-21.
Go to original source...
Go to PubMed...
- Krarup T, Hagen C. Autoimmun hypophysitis [Autoimmune hypophysitis]. Ugeskr Laeger 2010;172:875-880.
Go to PubMed...
- Bertrand A, Kostine M, Barnetche T et al. Immune related adverse events associated with anti‑CTLA-4 antibodies: systematic review and meta‑analysis. BMC Med 2015;13:211.
Go to original source...
Go to PubMed...
- Dillard T, Yedinak CG, Alumkal J et al. Anti‑CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13:29-38.
Go to original source...
Go to PubMed...
- Tsoli M, Kaltsas G, Angelousi A et al. Managing Ipilimumab‑Induced Hypophysitis: Challenges and Current Therapeutic Strategies. Cancer Manag Res 2020; 12: 9551-9561.
Go to original source...
Go to PubMed...
- Caturegli P, Newschaffer C, Olivi A et al. Autoimmune hypophysitis. Endocr Rev 2005;26:599-614.
Go to original source...
Go to PubMed...
- Falorni A, Minarelli V, Bartoloni E et al. Diagnosis and classification of autoimmune hypophysitis. Autoimmun Rev 2014;13:412-416.
Go to original source...
Go to PubMed...
- Bellastella G, Maiorino MI, Bizzarro A et al. Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary 2016;19:625-642.
Go to original source...
Go to PubMed...
- Joshi MN, Whitelaw BC, Carroll PV. Mechanisms in Endocrinology: Hypophysitis: diagnosis and treatment. Eur J Endocrinol 2018;179:151-163.
Go to original source...
Go to PubMed...
- Donadieu J, Rolon MA, Thomas C et al. Endocrine involvement in pediatric‑onset Langerhans' cell histiocytosis: a population‑based study. J Pediatr 2004;144:344-350.
Go to original source...
Go to PubMed...
- Joshi MN, Whitelaw BC, Palomar MT et al. Immune checkpoint inhibitor‑related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf) 2016;85:331-339.
Go to original source...
Go to PubMed...
- Faje AT, Sullivan R, Lawrence D et al. Ipilimumab‑induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014;99:4078-4085.
Go to original source...
Go to PubMed...
- Min L, Hodi FS, Giobbie‑Hurder A et al. Systemic high‑dose corticosteroid treatment does not improve the outcome of ipilimumab‑related hypophysitis: a retrospective cohort study. Clin Cancer Res 2015;21:749-755.
Go to original source...
Go to PubMed...
- Ryder M, Callahan M, Postow MA et al. Endocrine‑related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371-381.
Go to original source...
Go to PubMed...
- Angelousi A, Alexandraki KI, Tsoli M et al. Hypophysitis (including IgG4 and immunotherapy). Neuroendocrinology 2020;110:822-835.
Go to original source...
Go to PubMed...
- Larkin J, Chiarion‑Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.Další literatura u autorů a na www.casopisvnitrnilekarstvi.cz
Go to original source...
Go to PubMed...
- Da L, Teng Y, Wang N et al. Organ‑specific immune‑related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta‑analysis of randomized controlled trials. Front Pharmacol 2020;10:1671.
Go to original source...
Go to PubMed...
- Barroso‑Sousa R, Barry WT, Garrido‑Castro AC et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta‑analysis. JAMA Oncol 2018;4:173-182.
Go to original source...
Go to PubMed...
- Shang YH, Zhang Y, Li JH et al. Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta‑analysis. Immunotherapy 2017;9:261-272.
Go to original source...
Go to PubMed...
- Kassi E, Angelousi A, Asonitis N et al. Endocrine‑related adverse events associated with immune‑checkpoint inhibitors in patients with melanoma. Cancer Med 2019;8:6585-6594.
Go to original source...
Go to PubMed...
- Madan RA, Mohebtash M, Arlen PM et al. Ipilimumab and a poxviral vaccine targeting prostate‑specific antigen in metastatic castration‑resistant prostate cancer: a Phase 1 dose‑escalation trial. Lancet Oncol 2012;13:501-508.
Go to original source...
Go to PubMed...
- Hodi FS, Lawrence D, Lezcano C et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2:632-642.
Go to original source...
Go to PubMed...
- Di Giacomo AM, Ascierto PA, Pilla L et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT‑M1): an open‑label, single‑arm Phase 2 trial. Lancet Oncol 2012;13:879-886.
Go to original source...
Go to PubMed...
- Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first‑line treatment in stage IIIB/IV non‑small‑cell lung cancer: results from a randomized, double‑blind, multicenter Phase II study. J Clin Oncol 2012; 30: 2046-2054.
Go to original source...
Go to PubMed...
- Haanen JB, Thienen H, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol 2015; 42: 423-428.
Go to original source...
Go to PubMed...
- Caturegli P, Di Dalmazi G, Lombardi M et al. Hypophysitis Secondary to Cytotoxic T‑Lymphocyte‑Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol 2016;186:3225-3235.
Go to original source...
Go to PubMed...
- Albarel F, Gaudy C, Castinetti F et al. Long‑term follow‑up of ipilimumab‑induced hypophysitis, a common adverse event of the anti‑CTLA-4 antibody in melanoma. Eur J Endocrinol 2015;172:195-204.
Go to original source...
Go to PubMed...
- van der Vliet HJ, Perenboom RM. Multiple pseudotumors in IgG4-associated multifocal systemic fibrosis. Ann Intern Med 2004;141:896-897.
Go to original source...
Go to PubMed...
- Wallace ZS, Deshpande V, Mattoo H et al. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty‑Five Patients. Arthritis Rheumatol 2015;67:2466-2475.
Go to original source...
Go to PubMed...
- Girschikofsky M, Arico M, Castillo D et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro‑Histio‑Net. Orphanet J Rare Dis 2013;8:72.
Go to original source...
Go to PubMed...
- Nanduri VR, Bareille P, Pritchard J et al. Growth and endocrine disorders in multisystem Langerhans' cell histiocytosis. Clin Endocrinol (Oxf) 2000;53:509-515.
Go to original source...
Go to PubMed...
- Stern BJ. Neurologic sarcoidosis. https://www.uptodate.com/contents/neurologic‑sarcoidosis